Processa Pharmaceuticals, Inc. Proceeds from Debt, Net of Issuance Costs
Processa Pharmaceuticals, Inc. (PCSA) reported Proceeds from Debt, Net of Issuance Costs of $200.00 thousand for the 1-month period ending 2026-02-28, per its 10-K filed 2026-03-18.
Financial Statements › Cash Flow › Financing Activities
us-gaap:ProceedsFromDebtNetOfIssuanceCosts · last filed 2026-03-18
- 2026-02-28: Proceeds from Debt, Net of Issuance Costs 1 month $200.00K.
| Period end | Proceeds from Debt, Net of Issuance Costs 1 month |
|---|---|
| 2026-02-28 | $200.00K 10-K · filed 2026-03-18 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AMARIN CORP PLC\UK (AMRN) | $0.005B | -247.24 | |
| Xenetic Biosciences, Inc. (XBIO) | United States | $0.006B | |
| ProPhase Labs, Inc. (PRPH) | United States | $0.006B | -0.06 |
| Dermata Therapeutics, Inc. (DRMA) | United States | $0.005B | -0.62 |
| REVIVA PHARMACEUTICALS HOLDINGS, INC. (RVPH) | United States | $0.005B | |
| Cadrenal Therapeutics, Inc. (CVKD) | United States | $0.004B | -0.90 |
| Pulmatrix, Inc. (PULM) | United States | $0.006B | |
| Lakewood-Amedex Biotherapeutics Inc. (LABT) | United States | $0.004B | |
| Ernexa Therapeutics Inc. (ERNA) | United States | $0.006B | |
| 60 DEGREES PHARMACEUTICALS, INC. (SXTP) | United States | $0.004B | -0.59 |